The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Gaviscon Advance Oral Suspension Sodium alginate 500 mg, Potassium hydrogen carbonate 100 mg.



Reckitt Benckiser Ireland LtdPA0979/011/001

Main Information

Trade NameGaviscon Advance Oral Suspension Sodium alginate 500 mg, Potassium hydrogen carbonate 100 mg.
Active SubstancesPotassium hydrogen carbonate
Sodium alginate
Dosage FormOral suspension
Licence HolderReckitt Benckiser Ireland Ltd
Licence NumberPA0979/011/001

Group Information

ATC CodeA02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)

Status

License statusAuthorised
Licence Issued14/08/1998
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back